We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
- Authors
Lafage-Proust, Marie-Hélène
- Abstract
Zoledronate, a potent third-generation amino-bisphosphonate previously used for the treatment of bone metastasis, was recently shown to significantly reduce the risk of vertebral and hip fractures in osteoporotic postmenopausal women when infused at a dose of 5 mg per year for 3 years. The renal follow-up of this pivotal study that included more than 5,000 patients (estimated creatinine clearance >30 ml per min) is reported by Boonen et al. and shows the long-term renal safety of zoledronate in this osteoporotic population.Kidney International (2008) 74, 557–559. doi:10.1038/ki.2008.344
- Subjects
BONE fracture prevention; AMINO compounds; OSTEOPOROSIS in women; BONE metastasis; RENAL biopsy; THERAPEUTICS
- Publication
Kidney International, 2008, Vol 74, Issue 5, p557
- ISSN
0085-2538
- Publication type
Article
- DOI
10.1038/ki.2008.344